Literature DB >> 18249391

Clinical uses of anti-Müllerian hormone assays: pitfalls and promises.

Isabelle Streuli1, Timothee Fraisse, Charles Chapron, Gérard Bijaoui, Paul Bischof, Dominique de Ziegler.   

Abstract

OBJECTIVE: To investigate whether the controversy about fluctuations of anti-Müllerian hormone (AMH) levels during the menstrual cycle results from differences between the immunoassays currently available: the Beckman Coulter Immunotech kit (Fullerton, CA) and the Diagnostic Systems Laboratories kit (Webster, TX).
DESIGN: Prospective trial.
SETTING: Fertility clinics of two tertiary university hospitals. PATIENT(S): One hundred sixty-eight blood samples from three different populations. Serial samples at set intervals from the LH surge were taken in a fourth population of 10 volunteers. INTERVENTION(S): We remeasured AMH levels by using the Diagnostic Systems Laboratories kit in 168 blood samples in which AMH initially had been measured by using the Beckman Coulter assay. We also conducted serial AMH measurements (n = 7) during the menstrual cycle of 10 women. MAIN OUTCOME MEASURE(S): Linear regression of AMH levels determined by using 2 different assays and analysis of variance of serial measurements in the menstrual cycle. RESULT(S): We found a linear relationship between the 2 methods, with a correlation coefficient of 0.88. When repeated individual AMH measures were longitudinally analyzed in relation to the LH surge, a slight but significant decrease was observed after ovulation. CONCLUSION(S): Differences in AMH fluctuations during the menstrual cycle reported in recent publications do not result from the use of different AMH assays. The changes in AMH levels after ovulation are slight, yet statistically significant. However, the fluctuations observed are smaller than intercycle variability and therefore are not clinically relevant as far as AMH measurements for clinical purposes are concerned. In daily practice, AMH therefore can be measured anytime during the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18249391     DOI: 10.1016/j.fertnstert.2007.10.067

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  17 in total

1.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

2.  Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles.

Authors:  Clarisa R Gracia; Sanghyuk S Shin; Maureen Prewitt; Janna S Chamberlin; Lori R Lofaro; Kristin L Jones; Marta Clendenin; Katherine E Manzanera; Dennis L Broyles
Journal:  J Assist Reprod Genet       Date:  2018-03-14       Impact factor: 3.412

3.  Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization.

Authors:  Suresh Kini; H W Raymond Li; Dave Morrell; Sue Pickering; K Joo Thong
Journal:  J Assist Reprod Genet       Date:  2010-05-14       Impact factor: 3.412

Review 4.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.

Authors:  Jenny A Visser; Izaäk Schipper; Joop S E Laven; Axel P N Themmen
Journal:  Nat Rev Endocrinol       Date:  2012-01-10       Impact factor: 43.330

5.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

6.  Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.

Authors:  Cheng-Hsuan Wu; Yu-Ching Chen; Hsin-Hung Wu; Jyuer-Ger Yang; Yu-Jun Chang; Horng-Der Tsai
Journal:  J Assist Reprod Genet       Date:  2009-07       Impact factor: 3.412

7.  Comparability of antimüllerian hormone levels among commercially available immunoassays.

Authors:  H Irene Su; Mary D Sammel; Michael V Homer; Kim Bui; Carolyn Haunschild; Frank Z Stanczyk
Journal:  Fertil Steril       Date:  2014-04-14       Impact factor: 7.329

8.  Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles.

Authors:  Tsung-Hsien Lee; Chung-Hsien Liu; Chun-Chia Huang; Kung-Chen Hsieh; Pi-Mei Lin; Maw-Sheng Lee
Journal:  Reprod Biol Endocrinol       Date:  2009-09-17       Impact factor: 5.211

9.  Clinical application of anti-Müllerian hormone as a predictor of controlled ovarian hyperstimulation outcome.

Authors:  Jae Eun Lee; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh; Ki Chul Kim; Won Don Lee; Seok Hyun Kim
Journal:  Clin Exp Reprod Med       Date:  2012-12-31

10.  Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer.

Authors:  Pawel Walentowicz; Pawel Sadlecki; Magdalena Krintus; Grazyna Sypniewska; Aneta Mankowska-Cyl; Marek Grabiec; Malgorzata Walentowicz-Sadlecka
Journal:  Int J Endocrinol       Date:  2013-07-28       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.